Novan — Investor Presentation (March 2020)
23 slides from Novan's investor presentation, Mar 23, 2020
Slide 1: Corporate Overview March 2020
Exhibit 99.2 Corporate Overview March 2020 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements that reflect our current views with respect to, among other things, our plans to develop and commercialize our product candidates, including our interpretation of preclinical and clinical studies and the success and tim
Slide 3: Proprietary Nitricil Technology
Proprietary Nitricil™ Technology Creation of macromolecular New Chemical Entities (NCEs) that possess unique nitric oxide (NO) release profiles that can be tailored to different therapeutic uses Analytical Therapeutic Engineered Stable Science Quantities “Tunability” Macromolecule Storage Targeted d
Slide 4: Proprietary Nitricil Technology
Proprietary Nitricil™ Technology NO NO NO NO NCE NO H20 NO NO NO NO NO NO NO 4
Slide 5: Tunability and Release Profiles
Tunability and Release Profiles Generic Examples Novan Specific NCEs Burst Phase Time NO Time - Real Sustained Phase Release (nmol) Release Time NO Release NO Time - Real Time (Hr) Maximum Sustained Phase Released Burst % of Total NO ofTotal % NO Released NO Phase Cumulative Quantity Cumulative of T
Slide 6: Science & Technology
Science & Technology Macromolecular platform to achieve stable, tunable and druggable delivery of nitric oxide Stable Tunable Druggable Real-Time Nitric Oxide Release Extended Tail Initial Burst New Chemical Entity (NCE) Proprietary platform enabling development of NCEs with Proprietary formulations
Slide 7: Development Pipeline
Development Pipeline Product Indication Preclinical Phase 1 Phase 2 Phase 3 Candidates DERMATOLOGY SB206 Molluscum Current focus, progression subject to additional funding and FDA feedback Atopic Dermatitis SB414 Psoriasis SB204 Acne Vulgaris SB208 Tinea Pedis MEN’S AND WOMEN’S HEALTH SB206 Genital
Slide 8: Value of Extensive Human Clinical Data
Value of Extensive Human Clinical Data SB204 SB206 SB208 SB414 Phase 3 (MC), Phase 2 (TP), Clinical Progress Phase 3 Phase 1b Phase 2 (EGW) Phase 1 (Nail) Tinea pedis, nail Atopic dermatitis, Indications Acne vulgaris Molluscum, EGW growth psoriasis Anti-bacterial, Anti-bacterial, Mechanism of Actio
Slide 9: SB206 Phase 3 Study Design (B-SIMPLE1, B-SIMPLE2)
SB206 Phase 3 Study Design (B-SIMPLE1, B-SIMPLE2) • Multi-center, randomized, double-blind, vehicle-controlled, parallel trials to evaluate the efficacy and Description safety of SB206 12% QD for the treatment of molluscum contagiosum (“molluscum” or “MC”) • ~340 subjects per pivotal trial • 2:1 (ac
Slide 10: Study Demographics
Study Demographics1 B-SIMPLE1 B-SIMPLE2 SB206 Vehicle SB206 Vehicle ITT Population2 236 116 237 118 PP Population3 192 109 194 103 Prematurely Discontinued Prior to Week 12 (%) 37 (15.7%) 4 (3.4%) 37 (15.6%) 14 (11.9%) Number of Sites 33 33 % Dermatologists 66.7% 69.7% Age (years) Mean 7.3 6.7 6.3 6
Slide 11: Stratification at Randomization
Stratification at Randomization1,2 B-SIMPLE1 B-SIMPLE2 SB206 Vehicle SB206 Vehicle # of Subjects Randomized per Household 1 Subject 76.7% 81.4% 2 Subject 23.3% 18.6% # of Subjects Randomized by Investigator Type Dermatologists 60.2% 59.5% 59.9% 61.0% Other 39.8% 40.5% 40.1% 39.0% The Phase 3 B-SIMPL
Slide 12: Study Disposition
Study Disposition1,2 B-SIMPLE1 B-SIMPLE2 SB206 Vehicle SB206 Vehicle Prematurely Discontinued Treatments - Reasons 18.2% 5.2% 19.8% 11.9% Adverse Events 3.0% 0.9% 8.0% 0.8% Lost to Follow Up 8.5% 1.7% 5.9% 8.5% Lack of Efficacy 0.0% 0.0% 0.0% 0.0% Physician Decision 0.0% 0.0% 0.4% 0.0% Withdrawal by
Slide 13: B-SIMPLE1 & B-SIMPLE2 Top-Line Results: ITT Population
B-SIMPLE1 & B-SIMPLE2 Top-Line Results: ITT Population1 B-SIMPLE1 B-SIMPLE2 SB206 Vehicle SB206 Vehicle p-value p-value (n=236) (n=116) (n=237) (n=118) Primary Endpoint: Complete Clearance of 25.8% 21.6% p=0.375 30.0% 20.3% p=0.062 All Lesions at Week 12 Secondary Endpoint: Complete Clearance of 15.
Slide 14: Complete Clearance of All Lesions (ITT) by Week
Complete Clearance of All Lesions (ITT1) by Week B-SIMPLE1 B-SIMPLE2 Percentage of Patients with Complete Clearance at Percentage of Patients with Complete Clearance at Week 12 Week 12 35.0% 35.0% 30.0% 30.0% 30.0% 25.8% 25.0% 25.0% 21.6% 20.3% 20.0% 20.0% 15.3% 15.0% 15.0% 13.9%* 10.3% 10.0% 10.0%
Slide 15: Percent Change from Baseline Lesion Count
Percent Change from Baseline Lesion Count B-SIMPLE1 B-SIMPLE2 10% 10% 0% 0% Week 2 Week 4 Week 8 Week 12 Week 2 Week 4 Week 8 Week 12 -10% -10% -20% -20% * -30% * -30% * -40% -40% -50% -50% * * -60% -60% Vehicle SB206 Vehicle SB206 * * p-value <0.05 15
Slide 16: Sensitivity Analyses and Exploratory Endpoints
Sensitivity Analyses and Exploratory Endpoints B-SIMPLE1 B-SIMPLE2 SB206 Vehicle SB206 Vehicle p-value p-value (n=192) (n=109) (n=194) (n=103) PP Primary Endpoint: Complete Population1 Clearance of All Lesions at Week 12 31.3% 21.1% p=0.074 36.1% 23.3% p=0.028 SB206 Vehicle SB206 Vehicle p-value p-v
Slide 17: Complete Clearance by Household Stratification Factor
Complete Clearance Count at Week 12 (ITT1) by Household Stratification Factor B-SIMPLE1 B-SIMPLE2 SB206 Vehicle SB206 Vehicle p-value p-value n=236 n=116 n=237 n=118 One-Subject Household 28.7% 19.1% p=0.116 29.0% 16.7% p=0.025 n=181 n=89 n=193 n=96 Two-Subject Household 16.4% 29.6% - 34.1% 36.4% -
Slide 18: B-SIMPLE1 & B-SIMPLE2: Consistent and Supportive
B-SIMPLE1 & B-SIMPLE2: Consistent and Supportive • Statistical test of heterogeneity evaluated the consistency across B-SIMPLE1, B-SIMPLE2 and the integrated data • Overlap of 95% confidence intervals (interval that one can be 95% confident contains the true value of the population) for the primary
Slide 19: Overall Summary of AEs (Safety Population)
Overall Summary of AEs (Safety Population) at Week 24 B-SIMPLE1 B-SIMPLE2 SB206 Vehicle SB206 Vehicle (N=235) (N=116) (N=237) (N=117) Subjects with at least one Treatment Emergent 115 (48.9%) 36 (31.0%) 120 (50.6%) 30 (25.6%) Adverse Event (TEAE) Subjects with at least one Serious TEAE 0 0 1 (0.4%)
Slide 20: Summary of Treatment-Emergent Adverse Events at Week 24
Summary of Treatment-Emergent Adverse Event (Safety Population) at Week 24 B-SIMPLE1 B-SIMPLE2 SB206 Vehicle SB206 Vehicle (N=235) (N=116) (N=237) (N=117) System Organ Class/Preferred Term Subjects[1] Events Subjects[1] Events Subjects[1] Events Subjects[1] Events Subjects with at least one TEAE 115
Slide 21: SB206 Impact on Scarring
SB206 Impact on Scarring Number of Subjects (%) with Scarring by Visit (ITT Population) B-SIMPLE1 B-SIMPLE2 SB206 Vehicle SB206 Vehicle (N=236) (N=116) (N=237) (N=118) Week 4 0 0 8 (3.4%) 6 (5.1%) Week 8 7 (3.0%) 7 (6.0%) 7 (3.0%) 9 (7.6%) Week 12 6 (2.5%) 4 (3.4%) 12 (5.1%) 12 (10.2%) Week 24 11 (4
Slide 22: Summary of SB206 B-SIMPLE Program & Path Forward
Summary of SB206 B-SIMPLE Program & Path Forward • Top-line efficacy results announced January 2020 − SB206 failed to achieve statistically significant results for the primary endpoint − B-SIMPLE2 was statistically significant for multiple pre-specified sensitivity analyses − Similar analyses with B
Slide 23: Funding and Operations Commentary
Funding and Operations Commentary • Cash and cash equivalents of ~$13.7M as of 12/31/19 • Announced closing of $5.95M public offering on 3/3/20 • The Company continues to explore both financial as well as strategic options in order to continue operations and to progress SB206 for the molluscum indic